BEAMER is delighted to announce that its project lead Claire Everitt, the Device Design and Engineering Team Leader in R&D at Pfizer and Aad R. Liefveld, a project member, have authored an article titled ‘Understanding Human Behavior To Help Improve Patient Adherence‘ published in Clinical Leader.
Unveiling the Urgent Context:
This article has been published due to the recognition of patient behaviour as a pivotal factor influencing the outcome of a treatment. Despite considerable efforts within the healthcare industry to bolster patient adherence through various means such as improving patient experiences, and fostering collaborative decision-making between healthcare professionals and patients, statistics indicate that these efforts have not substantially impacted adherence rates. This is why the BEAMER project was set up – to help address the persistent issue of low adherence rates in patient treatment and support. It is specifically designed with the aim of enhancing patient support and improving treatment adherence within healthcare systems.
The article, accessible here, illuminates the crucial factors that impact treatment adherence in healthcare.
Targeting real-world adherence improvements: BEAMER’s main goal is to significantly improve real-world adherence by emphasizing the necessity for stakeholders to embrace a model that goes beyond theory, emphasising simplicity, practicality, proven effectiveness, and reliance on factors that we can influence.
Validated: Validation through clinical studies involving 18,000 patients across six diverse treatment areas aims to establish the model’s effectiveness and disease-agnostic understanding, crucial for its acceptance and implementation as the basis for practical solutions.
Clinical Care and Clinical Research: Non-adherence is considered a greater issue during clinical care than in clinical studies; however, genuine issues also exist in clinical studies. After decades of improving clinical studies, the early dropout rate, across all conditions, is still substantial: up to 30%. Non-adherence therefore has a major effect on timelines, costs, efficacy, and clinical data sets.
Where to read the article?
If you’re interested in discovering more, then click here to read the full article.
Our role at BEAMER:
ECHAlliance leads Work Package 6, overseeing communication and dissemination efforts within the project.
